Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disopyramide-associated liver dysfunction.

G L Bakris, P D Cross, J E Hammarsten

    Mayo Clinic Proceedings
    |April 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Disopyramide can cause cholestatic jaundice and liver dysfunction, typically within the first week of treatment. Stopping the drug often resolves symptoms, but abnormalities may persist long-term.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Hyperkalaemia in diabetes: a silent risk predicting poor outcomes.

    Diabetic medicine : a journal of the British Diabetic Association·2018
    Same author

    Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease.

    Clinical pharmacology and therapeutics·2017
    Same author

    Masked and Nocturnal Hypertension in the ARTS-DN ABPM Sub-Study with Finerenone.

    Journal of the American Society of Hypertension : JASH·2016
    Same author

    The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension.

    Journal of the American Society of Hypertension : JASH·2016
    Same author

    The Medical Bookshelf.

    Postgraduate medicine·2016
    Same author

    Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.

    Clinical pharmacology and therapeutics·2014
    Same journal

    Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

    Mayo Clinic proceedings·2026
    Same journal

    37-Year-Old Woman With Jaundice.

    Mayo Clinic proceedings·2026
    Same journal

    34-Year-Old Woman With An Unidentified Overdose.

    Mayo Clinic proceedings·2026
    Same journal

    Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

    Mayo Clinic proceedings·2026
    Same journal

    Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

    Mayo Clinic proceedings·2026
    Same journal

    RAAS Inhibition in the ICU: Stop, Continue, or Restart?

    Mayo Clinic proceedings·2026
    See all related articles

    Area of Science:

    • Hepatology
    • Clinical Pharmacology

    Background:

    • Disopyramide is an antiarrhythmic medication.
    • Liver dysfunction is a potential adverse effect of drug therapy.

    Observation:

    • A case of disopyramide-associated cholestatic jaundice is presented.
    • A review of reported cases of disopyramide-associated liver dysfunction was conducted.

    Findings:

    • Liver dysfunction manifestations usually appear within the first week of disopyramide treatment.
    • Discontinuation of disopyramide often leads to prompt clinical resolution.
    • In rare cases, laboratory abnormalities may persist for up to 18 months.

    Implications:

    • Physicians should be aware of disopyramide-induced liver injury.
  • Early recognition and drug discontinuation are crucial for managing this rare complication.